Leptin
Also known as: LEP, Metreleptin, Myalept, Myalepta, Ob gene product, OB protein, rmetHuLeptin
Source Leptin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Leptin is an adipokine hormone that circulates in the blood and reflects the amount of body fat. It is used clinically as the recombinant product metreleptin to replace deficient hormone in rare congenital leptin deficiency. Research also examines leptin as a biomarker of inflammation, metabolic disease, and eating disorders.
Mechanism of Action
Leptin is secreted by adipocytes and enters the circulation, where it interacts with leptin receptors on target cells. Changes in circulating leptin concentrations are linked to appetite regulation, energy expenditure, and inflammatory pathways, making it a useful indicator of metabolic and immune status.
What the Research Shows
Meta‑analyses of randomized trials in type 2 diabetes show that GLP‑1 receptor agonists lower circulating leptin alongside other inflammatory markers (SMD -0.67) (Ren et al., 2025). A systematic review of anorexia nervosa identified significantly reduced leptin levels in patients versus controls (Wu et al., 2024). In polycystic ovary syndrome, plasma leptin is listed among many factors potentially influencing recurrent pregnancy loss (Wartena & Matjila, 2023). Classification of congenital leptin deficiency identified 28 variants and confirmed that metreleptin treatment can be applied to classical and biologically inactive forms (von Schnurbein et al., 2024). Exercise training in type 2 diabetes patients modestly reduces leptin levels, contributing to broader metabolic improvements (García‑Hermoso et al., 2023).
Reported Benefits
Recombinant metreleptin restores missing hormone in patients with congenital leptin deficiency, leading to improved appetite control and weight outcomes as reported in variant‑specific analyses (von Schnurbein et al., 2024). GLP‑1 receptor agonists produce secondary reductions in leptin, which may contribute to their anti‑inflammatory effects in diabetes (Ren et al., 2025). Regular aerobic or resistance exercise also lowers leptin concentrations, supporting metabolic benefits in type 2 diabetes (García‑Hermoso et al., 2023).
Limitations of the Evidence
Most leptin data arise from secondary outcomes in meta‑analyses or biomarker studies rather than dedicated leptin‑targeted trials, limiting causal inference. The GLP‑1 agonist and exercise findings reflect modest effect sizes and heterogeneous study designs. Evidence for leptin as a therapeutic target beyond rare deficiency remains sparse, and the relevance of leptin changes to clinical endpoints is not fully established.
Safety Considerations
Leptin (metreleptin) is a prescription product, but the abstracts provide limited information on adverse effects. Safety data are therefore sparse in the cited literature, and clinicians must rely on product labeling and post‑marketing surveillance for guidance. Monitoring for immune reactions or antibody formation is generally advised for biologic therapies, though specific rates are not detailed in the sources.
How It Is Administered
Metreleptin is administered by injection, most commonly via subcutaneous route; intravenous administration is also listed in the product profile. Formulations are supplied as sterile solutions for injection and are used under medical supervision.
Routes of Administration
Goals & Uses
- Generalized lipodystrophyMetabolic DiseaseHigh
- Congenital leptin deficiencyGenetic Metabolic DisorderHigh
- Treatment of generalized lipodystrophyMetabolic DiseaseHigh
- Neuroendocrine restoration in hypothalamic amenorrheaReproductive EndocrinologyModerate
- Appetite suppression / weight managementObesityLow
- Partial lipodystrophy managementMetabolic DiseaseModerate
- Congenital leptin deficiency treatmentRare Genetic DiseaseModerate
- Immune modulationImmunologyLow
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- General obesity without lipodystrophyOff Label Use RiskHigh
- Hypersensitivity to metreleptinAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Anti‑leptin antibodiesImmunologicModerate
Adverse Effects
- HypoglycemiaMetabolicUncommonAbnormally low blood glucose
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Anti-metreleptin antibodiesImmunogenicityCommon
- Weight loss / decreased appetiteMetabolicCommon
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
- LymphomaOncologyRare
- Anti‑leptin antibody formationImmunologicRare
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- ThiazolidinedionesLow
- SulfonylureasModerateMay increase risk of low blood sugar
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Renal impairmentOrgan ImpairmentRelative
- Obese patients without leptin deficiencyMetabolicRelative
- Patients with congenital leptin deficiencyGeneticAbsolute
- Pediatric patients (<2 years)AgeRelative
Regulatory Status
- European UnionApprovedApproved: Generalized lipodystrophy, Leptin deficiencyApproved under EMA.
- United StatesApprovedApproved: Congenital leptin deficiency, Generalized lipodystrophyMetreleptin (Myalept) FDA‑approved.
- United KingdomApprovedApproved: Generalized lipodystrophy, Leptin deficiencyMHRA approval.
Metreleptin (Myalept) is FDA‑approved for leptin deficiency and generalized lipodystrophy; other indications remain investigational.
Evidence & Sources
- Journal ArticleHighRen Y, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleHighWartena R, Matjila M2023-01-01T00:00:00.000000Z
- Journal ArticleHighWu YK, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighAsbaghi O, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighvon Schnurbein J, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighGarcía-Hermoso A, et al.2023-01-01T00:00:00.000000Z
Frequently Asked Questions
What medical condition is metreleptin approved to treat?
Metreleptin is approved as a prescription therapy for patients with congenital leptin deficiency, where it replaces the absent hormone and helps control appetite and body weight (von Schnurbein et al., 2024).
How do GLP‑1 receptor agonists affect leptin levels?
In a meta‑analysis of 52 randomized trials, GLP‑1 receptor agonists significantly reduced circulating leptin compared with placebo or standard diabetes treatments (standardized mean difference -0.67) (Ren et al., 2025).
Can exercise change leptin concentrations?
A systematic review of randomized trials found that structured exercise training in type 2 diabetes patients modestly lowered leptin levels, contributing to overall metabolic improvements (García‑Hermoso et al., 2023).
Is leptin useful as a biomarker for eating disorders?
Meta‑analysis of studies on anorexia nervosa reported that patients have significantly lower leptin concentrations than healthy controls, indicating its potential as a biomarker of starvation‑related metabolic changes (Wu et al., 2024).
What are the main safety concerns with metreleptin?
The cited literature does not detail specific adverse events. As a biologic injection, safety monitoring is recommended, and clinicians should refer to official prescribing information for known risks such as hypersensitivity or antibody formation.
What is Leptin?
Leptin is an adipokine hormone that circulates in the blood and reflects the amount of body fat. It is used clinically as the recombinant product metreleptin to replace deficient hormone in rare congenital leptin deficiency. Research also examines leptin as a biomarker of inflammation, metabolic disease, and eating disorders.
What is Leptin used for?
Leptin is educationally associated with: Generalized lipodystrophy, Congenital leptin deficiency, Treatment of generalized lipodystrophy, Neuroendocrine restoration in hypothalamic amenorrhea, Appetite suppression / weight management, Partial lipodystrophy management, Congenital leptin deficiency treatment, Immune modulation. Educational only — not medical advice.
How is Leptin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Leptin?
Reported adverse effects include: Hypoglycemia, Injection site reactions, Headache, Anti-metreleptin antibodies, Weight loss / decreased appetite, Injection site reaction, Lymphoma, Anti‑leptin antibody formation. This list is not exhaustive — consult a qualified clinician.
Who should avoid Leptin?
Recorded contraindications: Active malignancy, General obesity without lipodystrophy, Hypersensitivity to metreleptin, Pregnancy, Anti‑leptin antibodies. Consult a qualified clinician before use.